lgd-4033
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02578095)
Timeline
Indications
Mechanism of action
- Androgen ReceptorMODULATOR
AR modulator
SARM
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F- Mol. weight
- 338.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5170587 ↗
- ChEMBLCHEMBL3545356 ↗
Also known as
- lgd-4033
- lgd-4033
- vk5211
- vk5211
- vk-5211
- vk-5211
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05132049 | Phase 1 | Dec 13, 2021 | Dong-A Pharmaceutical |
| NCT02578095 | Phase 2 | Oct 1, 2015 | Viking Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dong-A Pharmaceutical | For profit | 1 | 1 | 1 | 2021 |
| Viking Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1